Please visit answersincme.com/GPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses bispecific antibodies in the current treatment landscape of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; and Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MNK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss strategies for the use of novel tyrosine kinase inhibitors (TKIs) in the management of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using novel TKIs for newly diagnosed CP-CML; Discuss the clinical implications of the latest data for first-line novel TKIs in CP-CML; and Outline potential considerations to optimize outcomes for newly diagnosed patients with CP-CML on first-line TKIs.

Please visit answersincme.com/GRK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses the role of antibody–drug conjugates (ADCs) in the treatment of HER2-positive metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; Review the efficacy and safety of HER2-directed antibody–drug conjugates (ADCs) for the treatment of HER2-overexpressing metastatic NSCLC; and Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC.

Please visit answersincme.com/EYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses approved and emerging TROP2-directed ADCs for the treatment of HR-positive, HER2-negative/low advanced breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for using TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced breast cancer; Discuss the clinical impact of approved and late-stage emerging TROP2-directed ADCs for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer; and Outline guideline-concordant, evidence-based strategies to appropriately incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced breast cancer.

Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better able to: Review guideline-recommended clinical strategies to reduce cervical cancer risk; Outline patient-focused strategies to increase acceptance of HPV vaccination across patient subpopulations; and Identify clinical approaches to enhance the uptake of recommended schedules for HPV vaccination.

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.

Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.

Please visit answersincme.com/860/93496951-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.